Mario Kratz1,2,3, Derek K Hagman1, Jessica N Kuzma1, Karen E Foster-Schubert2, Chun P Chan4, Skye Stewart4, Brian van Yserloo5, Emily O Westbrook6, David E Arterburn6, David R Flum3,4, David E Cummings2. 1. Division of Public Health Sciences, Cancer Prevention Program, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, USA. 2. Department of Medicine, Division of Metabolism, Endocrinology & Nutrition, University of Washington, Seattle, Washington, USA. 3. Department of Epidemiology, University of Washington, Seattle, Washington, USA. 4. Department of Surgery, University of Washington, Seattle, Washington, USA. 5. Diabetes Research Center, Virus Vector and Transgenic Mouse Core, University of Washington, Seattle, Washington, USA. 6. Group Health Research Institute, Seattle, Washington, USA.
Abstract
OBJECTIVE: Type 2 diabetes commonly goes into remission following Roux-en-Y gastric bypass (RYGB). As the mechanisms remain incompletely understood, a reduction in adipose tissue inflammation may contribute to these metabolic improvements. Therefore, whether RYGB reduces adipose tissue inflammation compared with equivalent weight loss from an intensive lifestyle intervention was investigated. METHODS:Sixteen people with obesity and type 2 diabetes were randomized to RYGB or lifestyle intervention. Fasting blood and subcutaneous abdominal adipose tissue were obtained before and after the loss of ∼7% of baseline weight. Adipose tissue inflammation was assessed by whole-tissue gene expression and flow cytometry-based quantification of tissue leukocytes. RESULTS: At 7% weight loss, insulin and metformin use were reduced among the RYGB but not the Lifestyle cohort, while fasting glucose and insulin declined in both. Adipose tissue inflammation increased modestly after RYGB and to a similar extent following nonsurgical weight loss. In both groups, the number of neutrophils increased severalfold (P < 0.001), mRNA levels of the proinflammatory cytokine interleukin-1β increased (P = 0.037), and mRNA expression of the anti-inflammatory and insulin-sensitizing adipokine adiponectin decreased (P = 0.010). CONCLUSIONS: A reduction in adipose tissue inflammation is not one of the acute weight loss-independent mechanisms through which RYGB exerts its antidiabetes effects.
RCT Entities:
OBJECTIVE:Type 2 diabetes commonly goes into remission following Roux-en-Y gastric bypass (RYGB). As the mechanisms remain incompletely understood, a reduction in adipose tissue inflammation may contribute to these metabolic improvements. Therefore, whether RYGB reduces adipose tissue inflammation compared with equivalent weight loss from an intensive lifestyle intervention was investigated. METHODS: Sixteen people with obesity and type 2 diabetes were randomized to RYGB or lifestyle intervention. Fasting blood and subcutaneous abdominal adipose tissue were obtained before and after the loss of ∼7% of baseline weight. Adipose tissue inflammation was assessed by whole-tissue gene expression and flow cytometry-based quantification of tissue leukocytes. RESULTS: At 7% weight loss, insulin and metformin use were reduced among the RYGB but not the Lifestyle cohort, while fasting glucose and insulin declined in both. Adipose tissue inflammation increased modestly after RYGB and to a similar extent following nonsurgical weight loss. In both groups, the number of neutrophils increased severalfold (P < 0.001), mRNA levels of the proinflammatory cytokine interleukin-1β increased (P = 0.037), and mRNA expression of the anti-inflammatory and insulin-sensitizing adipokine adiponectin decreased (P = 0.010). CONCLUSIONS: A reduction in adipose tissue inflammation is not one of the acute weight loss-independent mechanisms through which RYGB exerts its antidiabetes effects.
Authors: Stacy A Brethauer; Helen M Heneghan; Shai Eldar; Patrick Gatmaitan; Hazel Huang; Sangeeta Kashyap; Heather L Gornik; John P Kirwan; Philip R Schauer Journal: Surg Endosc Date: 2011-03-17 Impact factor: 4.584
Authors: Scott V Monte; Joseph A Caruana; Husam Ghanim; Chang Ling Sia; Kelly Korzeniewski; Jerome J Schentag; Paresh Dandona Journal: Surgery Date: 2011-11-16 Impact factor: 3.982
Authors: Melek C Arkan; Andrea L Hevener; Florian R Greten; Shin Maeda; Zhi-Wei Li; Jeffrey M Long; Anthony Wynshaw-Boris; Giuseppe Poli; Jerrold Olefsky; Michael Karin Journal: Nat Med Date: 2005-01-30 Impact factor: 53.440
Authors: Kristin L Campbell; Karen E Foster-Schubert; Karen W Makar; Mario Kratz; Derek Hagman; Ellen A Schur; Nina Habermann; Marc Horton; Clare Abbenhardt; Ling-Yu Kuan; Liren Xiao; Jerry Davison; Martin Morgan; Ching-Yun Wang; Catherine Duggan; Anne McTiernan; Cornelia M Ulrich Journal: Cancer Prev Res (Phila) Date: 2013-01-22
Authors: Ulrich Kintscher; Martin Hartge; Katharina Hess; Anna Foryst-Ludwig; Markus Clemenz; Martin Wabitsch; Pamela Fischer-Posovszky; Thomas F E Barth; Duska Dragun; Thomas Skurk; Hans Hauner; Matthias Blüher; Thomas Unger; Anna-Maria Wolf; Uwe Knippschild; Vinzenz Hombach; Nikolaus Marx Journal: Arterioscler Thromb Vasc Biol Date: 2008-04-17 Impact factor: 8.311
Authors: Joan Vendrell; Montserrat Broch; Nuria Vilarrasa; Ana Molina; Jose Manuel Gómez; Cristina Gutiérrez; Immaculada Simón; Joan Soler; Cristóbal Richart Journal: Obes Res Date: 2004-06
Authors: Derek K Hagman; Ilona Larson; Jessica N Kuzma; Gail Cromer; Karen Makar; Katya B Rubinow; Karen E Foster-Schubert; Brian van Yserloo; Peter S Billing; Robert W Landerholm; Matthew Crouthamel; David R Flum; David E Cummings; Mario Kratz Journal: Metabolism Date: 2017-02-02 Impact factor: 8.694
Authors: Katya B Rubinow; Jing H Chao; Derek Hagman; Mario Kratz; Brian Van Yserloo; Nilesh W Gaikwad; John K Amory; Stephanie T Page Journal: Am J Physiol Endocrinol Metab Date: 2017-07-11 Impact factor: 4.310
Authors: Brian F Zamarron; Cara E Porsche; Danny Luan; Hannah R Lucas; Taleen A Mergian; Gabriel Martinez-Santibanez; Kae Won Cho; Jennifer L DelProposto; Lynn M Geletka; Lindsey A Muir; Kanakadurga Singer; Carey N Lumeng Journal: Obesity (Silver Spring) Date: 2020-04-13 Impact factor: 5.002